Summary
Stryker Corporation announced a significant development through an 8-K filing on November 5, 2019, detailing a definitive agreement to acquire Wright Medical Group N.V. The acquisition will be initiated via a tender offer by Stryker's subsidiary, Stryker B.V., to purchase all outstanding ordinary shares of Wright Medical for $30.75 per share in cash. This move signals Stryker's intent to bolster its position in the medical technology market, particularly in areas where Wright Medical has a strong presence. The transaction is not contingent on financing, which is a positive indicator for deal certainty.
Key Highlights
- 1Stryker to acquire Wright Medical Group N.V. via a tender offer for $30.75 per share in cash.
- 2The acquisition is being pursued by Stryker B.V., a wholly-owned subsidiary of Stryker.
- 3The tender offer is conditional on at least 80% (potentially 95% or reduced by Stryker) of Wright Medical shares being tendered, along with regulatory approvals.
- 4The transaction is not subject to a financing condition, increasing deal certainty.
- 5Following the tender offer, Stryker may complete the acquisition through a Post-Offer Reorganization, which could involve mergers, asset sales, or a compulsory acquisition process.
- 6Customary representations, warranties, and covenants are included in the Purchase Agreement, with Wright Medical agreeing to operate its business in the ordinary course.
- 7Wright Medical may be required to pay a termination fee of $150 million under certain circumstances.
Frequently Asked Questions
This 8-K filing announces that Stryker Corporation has entered into a material definitive agreement to acquire Wright Medical Group N.V. It outlines the terms of the tender offer and the subsequent steps to complete the acquisition.
Stryker, through its subsidiary, will commence a tender offer to purchase all outstanding ordinary shares of Wright Medical for $30.75 per share in cash, without interest, subject to applicable tax withholdings.
The offer is subject to customary conditions, including the tender of at least 80% of Wright Medical's outstanding shares (with an initial minimum of 95% potentially reducible by Stryker), the expiration of antitrust waiting periods (like Hart-Scott-Rodino), and other required regulatory approvals. Wright Medical shareholder approval for certain resolutions related to the transaction is also a condition.
No, the filing explicitly states that the consummation of the Offer is not subject to a financing condition, which generally increases the likelihood that the transaction will be completed.